News | February 17, 2008

Drug-Coated Balloons Reduce Late Loss During Angioplasty of the Leg

February 18, 2008 - Treating patients who have occlusive femoropopliteal disease with paclitaxel-coated balloons during angioplasty — rather than the uncoated variety — leads to significant reductions in late lumen loss and target-lesion revascularization (TLR), according to a study published in the February 14, 2008, issue of The New England Journal of Medicine.

Data from the THUNDER (Local Taxane with short time contact for reduction of restenosis in distal arteries) trial, led by Gunnar Tepe, MD, of Eberhard Karls University (Tübingen, Germany), was presented in Washington, D.C., at the TCT 2007 symposium.
The trial, randomized 154 patients with stenosis of a femoropopliteal artery to treatment with angioplasty using paclitaxel-coated balloons, angioplasty with uncoated balloons but with paclitaxel dissolved in the contrast medium, or normal angioplasty without any additional paclitaxel (control). The results showed that at a 6-month follow-up, the paclitaxel-coated balloon group had significantly improved late loss and TLR, compared with controls.

The lack of effect in the patients treated with paclitaxel in the contrast medium differed from previous findings in animal models. Dissolving paclitaxel in contrast medium is known to enhance drug solubility, but the authors explained that most studies examining this method were performed in the coronary circulation, which differs with respect to vessel diameter and capillary supply of the muscle from the peripheral circulation in the leg. The authors noted that this could explain why paclitaxel in the contrast medium failed to work in the THUNDER trial, because “these differences influence local drug effects,” they wrote.

Even though TLR was significantly reduced in the coated-balloon group, repeat revascularizations appeared to be angiographically — not clinically — driven since symptom measurements remained the same at six months.

The trial however does not offer a comparison to bare metal stents (BMS) for peripheral revascularization, despite increasing research now showing that BMS are better than angioplasty alone in treating lesions of the superficial femoral artery (SFA).

For more information: content.nejm.org/cgi/content/full/358/7/689

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Sponsored Content | Videos | EP Lab| May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Artery Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
Medtronic, IN.PACT Admiral DCB, drug-coated balloon, below-the-knee, European BTK IN.PACT clinical study, peripheral artery disease, PAD, launch
News | Peripheral Artery Disease (PAD)| March 09, 2017
Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a drug-coated balloon (DCB...
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
Overlay Init